Orchard Therapeutics Plc - ORTX STOCK NEWS

InsightAce Analytic reports that the global Cell and Gene Therapy Supply Chain/Logistics market was valued at US$ 1.23 Billion in 2022 and is projected to reach US$ 3.12 Billion by 2031, with a compound annual growth rate (CAGR) of 11.2% from 2023 to 2031. The report outlines the growing demand for customizable services and advanced IT solutions in supply chain management for cell and gene therapies, while highlighting challenges such as high funding costs and lack of standard protocols. Key players include Be The Match BioTherapies and Cryoport. The market is primarily driven by North America, with Asia Pacific expected to see faster growth.

ResearchAndMarkets.com has released the report "Global Genetic Disorders Partnering 2016-2023," providing a comprehensive overview of genetic disorder deals signed worldwide since 2016. The report captures key aspects including deal trends, financial terms, and the most active dealmakers in the biopharma industry. It includes detailed analyses of deal structures, contract documents, and financial metrics, such as headline values, upfront payments, and royalty rates. Covering multiple genetic disorders like Cystic Fibrosis and Huntington's Disease, this report aims to be an essential resource for stakeholders in genetic disorder collaborations.

Orchard Therapeutics (Nasdaq: ORTX) will present virtually at the Guggenheim Genomic Medicines and Rare Disease Day on April 4, 2023, at 1:35 PM ET. The live webcast will be accessible via the company's website, with a replay available afterward. Orchard aims to revolutionize treatments for genetic diseases through HSC gene therapy, modifying patients' blood stem cells to address the root causes of conditions. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio and is now advancing a comprehensive pipeline of therapies. For updates, visit the Orchard website or follow them on social media.

The report titled 'Germany Cell and Gene Therapy Market - Focused Insights 2023-2028' reveals that the market was valued at $0.34 billion in 2022 and is projected to reach $3.44 billion by 2028, growing at a 40.15% CAGR.

Key drivers include an increase in target patient populations and robust regulatory support. Zolgensma is highlighted as the first blockbuster therapy, having generated $1.37 billion in 2022. The market features over 1,000 ongoing CAR-T cell therapy clinical trials, with numerous companies, including Legend Biotech (LEGN) and Orchard Therapeutics (ORTX), leading the charge.